RecallRadar

FDA Drug recall D-1060-2020

Nystatin Oral Suspension, USP, 100,000 units per mL, Cherry/Peppermint Flavor, 16 fl oz (473 mL) bottle, Rx ONLY, pai Pharmaceutical Associ…

On 2020-04-01 the FDA classified a Class II recall of Nystatin Oral Suspension, USP, 100,000 units per mL, Cherry/Peppermint Flavor, 16 fl oz (473 mL) bottle, Rx ONLY, pai Pharmaceutical Associ… by Pai Holdings, citing subPotent Drug: Low out-of-specification results for assay testing.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-1060-2020
ClassificationClass II
Statusterminated
Initiated2020-03-19
Published2020-04-01
Last updated2026-09-13 11:52 UTC
CompanyPai Holdings
DistributionUS

Product

Nystatin Oral Suspension, USP, 100,000 units per mL, Cherry/Peppermint Flavor, 16 fl oz (473 mL) bottle, Rx ONLY, pai Pharmaceutical Associates, Inc., Greenville, SC 29605; NDC 0121-0810-16.

Reason

SubPotent Drug: Low out-of-specification results for assay testing.

Identifiers

ndc0121-0810-02
ndc0121-0810-16
ndc0121-4810-05
ndc0121-4810-40
ndc0121-4810-00
ndc0121-4810-50
code_infoLot: BE85, Exp. 11/2020

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1060-2020%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.